Abel Costa, MD @anetoc

Hematologist. Tweets are my own. São Paulo, Brasil Joined July 2010

Tweets

477
Followers

704
Following

667
Likes

2K

Abel Costa, MD @anetoc

6 months ago

Our new review on AI in lymphoma diagnosis is out. A realistic look at how AI can support — not replace — clinical practice. Grateful to Marianne for the invitation and collaboration. 🔗 Link: rdcu.be/eWYH5

0 0 1 67 0

View Details

OncoDaily @oncodaily

6 months ago

EPCORE FL-1 Trial Shows Promising Results for Follicular Lymphoma - @anetoc oncodaily.com/voices/abel-co… #Cancer #OncoDaily #Oncology #MedEd #MedTwitter #MedX #MedOnc @CancerWorldmag

0 1 3 135 0

View Details

Abel Costa, MD @anetoc

7 months ago

#ASH2025 was a meaningful milestone in my academic journey. Being an author on 4 oral presentations and 3 posters highlights the strength of collaborative clinical research and team science. Grateful to my mentor Eduardo Rego and the IDOR research team.

0 0 2 191 0

View Details

Abel Costa, MD @anetoc

7 months ago

One of the moments I was most proud of at #ASH2025 was seeing Luiza Lapolla present data from the Brazilian AML Registry, highlighting how social determinants shape AML outcomes using real-world national data. @abhhoficial

0 0 4 203 0

View Details

Abel Costa, MD @anetoc

7 months ago

Glad to contribute as an author to an oral presentation at #ASH2025 on golca ± rituxi in R/R FL. High ORR, durable responses, and manageable toxicity, even in heavily pretreated patients, supporting the role of targeted combinations in later lines.

0 0 0 73 0

View Details

Abel Costa, MD @anetoc

7 months ago

Grateful to contribute as an author to the TRAVERSE phase 2 study presented at #ASH2025. A chemotherapy-free triplet regimen, AVR in treatment-naïve MCL, showed deep responses and high MRD negativity, even in biologically high-risk subgroups.

0 0 3 266 1

View Details

Abel Costa, MD @anetoc

7 months ago

For those who want to dive deeper, the full EPCORE FL-1 data are published in The Lancet and have already led to FDA and ANVISA approval. thelancet.com/journals/lance…

0 0 1 45 0

View Details

Abel Costa, MD @anetoc

7 months ago

Truly grateful and proud to be part of a defining moment at #ASH2025. Contributing as an author to the EPCORE FL-1 trial — with simultaneous publication in @TheLancet and global regulatory impact — was a very special milestone in my academic journey. 🧵👇

11 0 12 627 1

View Details

Abel Costa, MD @anetoc

7 months ago

Taken together, EPCORE FL-1 shows that epcoritamab + R² achieves deep and durable responses, delays the need for subsequent therapy, and maintains a predictable, manageable safety profile, supporting its role as a new standard of care.

0 0 1 86 0

View Details

Abel Costa, MD @anetoc

7 months ago

🇧🇷 Proud to represent Brazil in this milestone and to be part of a global study with strong participation from Brazilian centers, contributing to a change in standard of care.

0 0 0 34 0

View Details

Abel Costa, MD @anetoc

7 months ago

Why this matters: ✔️First bispecific antibody approved in combination for FL ✔️Fixed-duration, chemotherapy-free regimen ✔️Immediate impact on treatment sequencing and clinical practice

0 0 0 34 0

View Details

Abel Costa, MD @anetoc

7 months ago

Safety profile was manageable and predictable, with no new safety signals: • CRS mostly grade 1–2; no grade ≥3 CRS • No tx discontinuations due to CRS • Neutropenia and infections were manageable • >90% relative dose intensity maintained Compatible with outpatient delivery.

0 0 0 34 0

View Details

Abel Costa, MD @anetoc

7 months ago

Despite still maturing follow-up, EPCORE FL-1 shows a statistically significant early OS signal, with separation of the curves and an HR of 0.38, favoring epcoritamab + R².

0 0 0 78 0

View Details

Abel Costa, MD @anetoc

7 months ago

Beyond PFS, EPCORE FL-1 showed a meaningful improvement in time to next treatment, reinforcing the durability and real-world relevance of responses.

0 0 0 40 0

View Details

Abel Costa, MD @anetoc

7 months ago

Key efficacy results: • ORR: 95.7% vs 81.0% • CR: 83% vs 50% • 79% reduction in risk of progression or death (HR 0.21) Benefit consistent across prespecified subgroups.

0 0 0 46 0

View Details

Abel Costa, MD @anetoc

7 months ago

EPCORE FL-1 design: • Phase 3, global, randomized • Epcoritamab + R² vs R² • R/R FL after ≥1 prior line • Dual primary endpoints: ORR and PFS

0 0 0 84 0

View Details

Abel Costa, MD @anetoc

7 months ago

Follicular lymphoma remains a chronic disease for most patients, with diminishing benefit after each line of therapy. EPCORE FL-1 addressed a critical unmet need: a fixed-duration, chemo-free strategy capable of delivering deep and durable remissions.

0 0 2 66 0

View Details

Toby Eyre @tobyeyre82

11 months ago

Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† - Annals of Oncology annalsofoncology.org/article/S0923-…

6 50 142 11K 70

View Details

EMN @EMN_EuMMnet

12 months ago

📢We are proud to announce that the EHA-EMN guidelines for the diagnosis, treatment and follow-up of #MultipleMyeloma are now available online! Huge thanks to Evangelos Terpos for coordinating such outstanding work! 👉nature.com/articles/s4157… @thanosdimop @EHA_Hematology

1 15 27 1K 3

View Details

Graham Collins @graham74GC

a year ago

Nivo-AVD vs BV-AVD in older pts (60+) with #Hodgkin. S1826 data. 99 eligible pts. 2y PFS • 89% Nivo-AVD • 64% BV-AVD 55% discontinued BV, 14% Nivo NRM 16% BV-AVD, 6% Nivo-AVD Transformational. If only we had access! #lymsm ascopubs.org/doi/10.1200/JC…